XML 87 R74.htm IDEA: XBRL DOCUMENT v3.24.1
Segment reporting (Details)
$ in Millions
3 Months Ended 6 Months Ended
Feb. 29, 2024
USD ($)
Feb. 28, 2023
USD ($)
Feb. 29, 2024
USD ($)
segment
Feb. 28, 2023
USD ($)
Segment Reporting [Abstract]        
Number of reportable segments | segment     3  
Segment Reporting Information [Line Items]        
Sales $ 37,052 $ 34,862 $ 73,760 $ 68,244
Adjusted operating income (Non-GAAP measure) 900 1,215 1,588 2,229
Impairment of goodwill, intangibles and long-lived assets (13,090) 0 (13,090) 0
Acquisition-related costs (249) (148) (412) (187)
Acquisition-related amortization (270) (247) (545) (577)
Certain legal and regulatory accruals and settlements (242) (427) (324) (6,981)
Transformational cost management (197) (145) (306) (283)
Adjustments to equity earnings in Cencora (22) (31) (72) (117)
LIFO provision 0 (20) (48) (38)
Operating (loss) income (13,171) 197 (13,209) (5,954)
Reportable Segments | U.S. Retail Pharmacy        
Segment Reporting Information [Line Items]        
Sales 28,861 27,577 57,805 54,781
Adjusted operating income (Non-GAAP measure) 752 1,067 1,446 2,172
Reportable Segments | International        
Segment Reporting Information [Line Items]        
Sales 6,022 5,651 11,854 10,840
Adjusted operating income (Non-GAAP measure) 245 352 387 468
Reportable Segments | U.S. Healthcare        
Segment Reporting Information [Line Items]        
Sales 2,176 1,634 4,107 2,622
Adjusted operating income (Non-GAAP measure) (34) (159) (129) (311)
Corporate and Other        
Segment Reporting Information [Line Items]        
Sales (6) 0 (6) 0
Adjusted operating income (Non-GAAP measure) $ (63) $ (44) $ (117) $ (100)